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Abstract 
Background 
High shear force critically regulates platelet adhesion and thrombus formation during ischemic 
vascular events.  To identify genetic factors that influence platelet thrombus formation under 
high shear stress, we performed a genome-wide association study (GWAS) and confirmatory 
experiments in human and animal platelets. 
Methods and Results 
Closure times in the shear-dependent Platelet Function Analyzer (PFA)-100® were measured 
on healthy, non-diabetic European Americans (n=125) and African Americans (n=116).  A 
GWAS significant association (p<5X10-8) was identified with 2 SNPs within the SVIL gene (chr 
10p11.23) in African-Americans but not European Americans.  Microarray analyses of human 
platelet RNA demonstrated the presence of SVIL isoform 1 (supervillin) but not muscle-specific 
isoforms 2 and 3 (archvillin, SmAV).  SVIL mRNA levels were associated with SVIL genotypes 
(p≤0.02) and were inversely correlated with PFA-100 closure times (p<0.04) and platelet volume 
(p<0.02).  Leukocyte-depleted platelets contained abundant levels of the ~205 kD supervillin 
polypeptide.  To assess functionality, mice lacking platelet supervillin were generated and back-
crossed onto a C57BL/6 background.  Compared to controls, murine platelets lacking supervillin 
were larger by flow cytometry and confocal microscopy, and exhibited enhanced platelet 
thrombus formation under high shear, but not low shear, conditions.  
Conclusions 
We show for the first time that 1) platelets contain supervillin, 2) platelet thrombus formation in 
the PFA-100® is associated with human SVIL variants and low SVIL expression, and 3) murine 
platelets lacking supervillin exhibit enhanced platelet thrombus formation at high shear stress.  
These data are consistent with an inhibitory role for supervillin in platelet adhesion and arterial 
thrombosis. 
Key Words: platelets, genetics, thrombosis 
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Introduction 
 
Arterial thrombosis is a major cause of myocardial infarction (MI) and stroke.  Most clinical 
events occur when an atherosclerotic plaque ruptures to expose subendothelial collagen and 
von Willebrand factor (VWF).  These proteins bind to platelets triggering primary activation and 
granule secretion.1  Secretion of soluble agonists, including ADP, amplifies activation and leads 
to integrin activation, platelet-platelet aggregation and occlusive thrombus formation.  Platelets 
play a more prominent role in arterial thrombus formation than in venous thrombosis because 
the highly specialized initial platelet-VWF interaction is enhanced by shear stress, such as 
occurs in coronary arteries.2, 3 
Platelet reactivity varies greatly among individuals.  This variation exhibits strong 
heritability in both European Americans (EA) and African Americans (AA)4, which could explain 
some of the known genetic contribution to the risk of acute MI.5  Although genetic epidemiology 
screens have identified loci associated with MI risk6, our understanding of causative genes is 
limited.  The use of intermediate phenotypes to identify genes involved in the pathophysiology of 
arterial thrombosis can yield stronger genetic associations.7  Genome-wide association studies 
(GWAS) have led to the discovery of key molecules regulating human disease8 and have 
identified genetic variants and novel genes associated with platelet number, platelet volume and 
in vitro platelet aggregation.9, 10  However, no GWAS has identified genes associated with shear 
stress-dependent platelet function.  The Platelet Function Analyzer-100® (PFA-100) measures 
the time to platelet thrombus formation under a defined shear stress of 1500 sec-1 in whole 
blood.11  The assay requires platelet tethering to VWF, firm adhesion to collagen, platelet 
activation and secretion, and platelet aggregation mediated by VWF and fibrinogen.  Abnormal 
assay results correlate with platelet hyperfunction and hypofunction associated with acute 
coronary syndromes12-15 and bleeding disorders, respectively.16, 17  The aim of this study was to 
identify genetic factors that influence platelet reactivity and thrombus formation under high shear 
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stress.  We carried out a genome-wide screen with the PFA-100® to identify novel gene 
variants in AAs and EAs.  We identified a novel platelet gene, SVIL (encoding the cytoskeletal 
regulatory protein, supervillin), whose expression negatively regulates platelet reactivity and 
thrombus formation in both humans and mice. 
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Methods 
Subjects and platelet phenotyping.  The Platelet Genes and Physiology study was 
approved by the Institutional Review Boards of Baylor College of Medicine and Thomas 
Jefferson University, and informed consent was obtained from all volunteers.  Healthy donors 
were recruited between 2000-2006 in Houston, Texas.  Citrated whole blood was used to 
measure PFA-100® closure times in a collagen and ADP-impregnated cartridge (hereafter 
referred to as PFA-100ColA) within 30 min of phlebotomy.  A platelet aggregation response of 
<10% was considered as exposure to anti-platelet agents and reason for exclusion.    
Genotyping. Genomic DNA was extracted from leukocyte buffy coats with the Qiagen 
DNA extraction kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions.  
DNA from AAs was genotyped on the Illumina Hum1M Beadarray.  EA DNAs were genotyped 
on the Illumina Hum550k Beadarray.  Due to the lower levels of linkage disequilibrium (LD) in 
African populations a denser SNP micorarray was selected to genotype the DNA samples from 
AA individuals to improve tagging of causal variants.  
Statistical analysis.  Quality control was performed before statistical analysis.  Subjects 
were excluded for relatedness to other participants and for failing stringent genotyping quality 
control.  Individual genotypes that failed quality control were also removed (see Supplemental 
Methods for details). PFA-100ColA closure times were natural log transformed and tested for 
associations using an additive model within a linear regression framework.  All analyses of EA 
and AA samples were performed separately.  The potential confounders, age, sex, VWF 
activity, plasma fibrinogen level and platelet CD41 level were tested for significance using 
forward selection and significant covariates were retained within the model (p-value < 0.1).  
Principal Components Analysis (PCA) was also performed on the data using a subset of the 
SNP markers that are in linkage equilibrium (r2<0.3).18  To evaluate if there is inflation of the test 
statistic due to population substructure/admixture, lambda, was estimated when both no PCA 
components and when one through five PCA components were included in the linear regression 
  CIRCULATIONAHA/2012/091462/R2-6 
model.  For those SNPs that met GWAS significance (p-value < 5 X10-8) a dominance 
parameter was tested in a linear regression model in order to determine whether the data fit an 
additive model where the genetic effect for the heterozygous genotype is between that of the 
genetic effects for the two homozygous genotypes for the major, reference allele, and the minor 
allele. 
 Platelet gene expression analysis.  RNA from leukocyte-depleted platelets (LDP) was 
prepared for gene expression profiling in 29 healthy subjects.  LDP was prepared using density 
centrifugation followed by CD45-positive cell depletion of platelet rich plasma (PRP).19  As 
controls, RNA from PRP and from the CD45+ leukocyte fraction was extracted from 11 and 5 
subjects, respectively, using TRIzol® (Invitrogen, Carlsbad, CA).  Gene expression analysis was 
performed using the Sentrix BeadChip and BeadStation system from Illumina, Inc. (San Diego, 
CA).20 
 Platelet supervillin expression and correlation with PFA-100ColA.  LDP RNA was used 
to validate the SVIL microarray data.19  Total LDP RNA was reverse transcribed and PCR-
amplified using a sense primer in exon 1 and an antisense primer in exon 5.  Immunoblotting of 
6% SDS-PAGE gels was performed with 4 different anti-supervillin antibodies to verify platelet 
expression. Natural log transformed mRNA expression data from microarrays was plotted vs. 
PFA-100ColA closure times for the 23 individuals for whom both values were available.  
Pearson correlation r- and P-values were calculated using GraphPad Prism software (La Jolla, 
CA). 
 Mouse platelet phenotyping.   Mice lacking Svil were generated and back-crossed ten 
times onto a C57BL/6 background.  Svil-/- and control C57BL/6 mice were maintained by 
homozygous breeding.  Platelet thrombus formation under shear stress was measured using 
microfluidic flow chambers with immobilized collagen.21  Blood from 3 wild type and 3 Svil -/- 
mice was studied.  Experiments were performed over 4 different days, with 3-4 runs per day (a 
“run” defined as data acquisition from platelet deposition in a single flow chamber) for a total of 
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15 runs per wild type and 15 runs per Svil -/- genotypes.  P values were computed using a two-
way repeated measures, linear mixed effects ANOVA model that accounts for the main effect of 
genotype with GraphPad Prism. 
 Flow Cytometry.  Whole blood was diluted into Tyrode’s buffer containing 1 mM CaCl2, 
and stained with FITC-α-CD41 (BD Pharmingen) or PE-α-GPIbα (Emfret Analytics, Würzburg, 
Germany).  After dilution with PBS the cells were analyzed on a FACScan. 
Immunofluorescence confocal microscopy.  Platelets adhered to glass slides statically, 
or to collagen coated coverslips statically or under high shear were stained with Alexa-568 
phalloidin and α-myosin IIA antibodies and imaged using confocal microscopy.  
Additional details are available in the Supplemental Methods.  
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Results 
SNPs within SVIL are associated with platelet function under shear stress 
 
To assess the capacity for platelet thrombus formation under shear stress, PFA-100ColA 
was used to measure PFA-100® closure times in a cohort of healthy, non-diabetic subjects (the 
Platelet Genes and Physiology [PGAP] study).  For this genetic study, only subjects self-
identified as EA or AA were considered.  Blood was collected for PFA-100ColA testing on 154 
AAs and 157 EAs.  The PFA-100ColA closure time data were normally distributed in both 
groups (not shown).  The DNA from each subject was genotyped for 620,901 or 1,070,000 
tagSNPs for EAs or AAs, respectively, using the Infinium II platform.  Exclusion criteria included 
NSAID use, subject relatedness and failing genotyping quality control (described in the Methods 
and in the Supplemental Materials). Table 1 summarizes the demographics of the 116 AA and 
125 EA subjects who were analyzed. 
The PFA-100ColA phenotype was tested for association with each genotype under an 
additive model.  Using log-transformed values of the PFA-100ColA phenotype, analysis was 
performed using linear regression, controlling for sex, age, CD41 and VWF activity in AAs, and 
sex and VWF activity in EAs.  For AAs, age (p=~10-2), sex (p=~10-2), CD41 (p=~10-2) and VWF 
activity (p=~10-9) were significant and were retained in the model.  For EAs, only sex (p=~10-2) 
and VWF activity (p=~10-9) were significant, so only these covariates were included in the 
analysis. PCA components were not included in the analysis, because lambda=1.0 indicating no 
inflation in the test statistic due to population substructure/admixture.  Figure 1A shows 
Manhattan plots for genotype associations with PFA-100ColA closure times, with a prominent 
“peak” observed in chromosome 10 for AAs.  Table 2 lists the SNPs with the 12 lowest P values 
for AAs.  Notably, 5 of these SNPs were clustered within ~21.8 kb of 4 exons within the SVIL 
gene, which encodes differentially spliced isoforms of supervillin and archvillin.  The most 
significant SNP, rs7070678 (p=3.6 x 10-8), which is a synonymous SNP in exon 14 of the SVIL 
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gene, is in LD with other SNPs within the SVIL gene but not with SNPs in neighboring genes 
(Figure 1B).  A second SNP, rs10826650, within the SVIL gene (intron 13) also reached GWAS 
significance (p<5X10-8).  Three additional SNPs (rs7910521, rs10826649, rs7913801) within 
introns 16 and 17 of the SVIL gene had p-values in the order of 10-6.  To determine whether or 
not an additive model best fit the data for the SNPs within the SVIL gene, a dominance 
parameter was included in the analysis.  However, because the dominance parameter was not 
significant, it was not included in the model.  This parameter was not significant, indicating no 
more explanatory power was derived from a dominant model. The closest other well-annotated 
genes in this region, LYZL1 (lysozyme-like 1) and KIAA1462, were >214 kb from the SVIL SNPs 
listed in Table 2, and there was no evidence of an association with either of these genes.  The 
clustering of SNPs with p values of ~10-8 suggested that genetic variants in SVIL (and not 
another gene) are associated with PFA-100ColA closure times in AAs.  No associations with 
GWAS significance were detected with SNP marker loci within the SVIL gene within EA, 
although 3 additional SVIL SNPs had weak associations in EA (p<10-2). 
 
Supervillin mRNA and protein are present in human and mouse platelets 
 
Figure 2 illustrates the SVIL exon structure, the two major known mRNAs and the 
location of rs7070678, the SNP with the strongest association with PFA-100ColA closure times.  
SVIL encodes supervillin, which has a broad cell distribution, and 2 archvillin isoforms, which 
are enriched in muscle.22-24  Supervillin forms a high-affinity link between the actin cytoskeleton 
and the plasma membrane22 but has not been described in platelets.  Because integrin function 
and rearrangements of the actin cytoskeleton are a crucial aspect of the platelet adhesive 
process25, we therefore sought to characterize supervillin in platelets. 
Platelet RNA expression analysis was performed with LDP RNA samples from 29 
healthy subjects.  Probes from the 5’-most and 3’-most exons (Figure 2A) were readily 
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detectable.  However, an RNA signal was not detected for probe ILMN_1659306, which is 
specific for archvillin and SmAV.  Platelet SVIL transcripts are expressed at moderately high 
levels, and are higher than PECAM-1 but lower than GPIb mRNAs (supplemental Figure 1).  
Supervillin transcripts were easily detected in LDP RNA by RT-PCR (Figure 2B), validating the 
microarray data.  Figure 2C shows SVIL mRNA levels for LDP, PRP and CD45+ leukocytes 
(WBC) as box plots.   
Western immunoblotting identified supervillin at ~205 kDa in PRP (Figure 3A).  This 
polypeptide migrated slightly faster than that seen in control A549 cells, so additional antisera 
was used to confirm platelet supervillin Mr and immunoreactivity.  The locations of the epitopes 
recognized by these antibodies are shown in Figure 3B.  In addition, because supervillin is 
present in leukocytes,26, 27 we also analyzed LDP and leukocyte-enriched buffy coat.  Using two 
other antibodies, 205 kDa supervillin was again detected in platelets, as well as in the 
megakaryocyte cell line, Meg-01, but was not detected in CD45-enriched leukocytes or K562 
erythroleukemia cells (Figure 3C, 3D).  Finally, supervillin was present in mouse platelets 
(Figure 3E).  Sequencing of platelet SVIL mRNA RT-PCR products revealed the same splice 
form as is present in HeLa cells (not shown).   
 
Supervillin mRNA levels correlate with platelet function under shear, platelet size and with the 
rs7070678 genotype 
 
 Because platelet protein was available from only a few of the 29 subjects used in the 
platelet RNA expression analysis, we used SVIL mRNA levels to test for a correlation with 
platelet function.  Figure 4A shows that SVIL mRNA levels correlate with PFA-100ColA closure 
times (p = 0.038).  Since longer closure times indicate reduced platelet function, these data 
suggest SVIL expression may inhibit human platelet thrombus formation under shear stress.  A 
trend was observed for a similar relationship between SVIL mRNA expression and collagen-
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induced platelet aggregation (p = 0.07), but not with ADP-induced platelet aggregation (p = 
0.23; data not shown).  SVIL mRNA levels also correlated negatively with human mean platelet 
volume (p = 0.016) (Figure 4B).  Because both SVIL SNPs and SVIL transcripts were 
associated with PFA-100ColA closure times (Figures 1 and 4), we tested whether SVIL SNPs 
were associated with SVIL mRNA levels using a recessive model analysis.  Figure 4C shows 
that SVIL expression differed significantly by rs7070678 genotype. 
 
Platelets from Svil deficient mice form thrombi faster under shear in flow chamber studies 
 
To further address the role of supervillin in platelet function, we generated mice from 
BayGenomics ES cells bearing an insertion in the supervillin (Svil) gene (Figure 5).  In this 
mouse, a -galactosidase/neomycin phosphotransferase (-gal/neo) gene trap inserted into the 
large intron downstream of the 13th of the 34 coding exons (Figure 5A) disrupts expression of 
all characterized Svil splice-forms (not shown).22-24  The location of the insertion was verified by 
Southern blotting, which showed that a Bgl II restriction site from the pGT0lxf vector reduced the 
11.5-kb Bgl II fragment including coding exon 13 to 7.2 kb (not shown), and by PCR (Figure 5B) 
with primers specific for either the wild-type (WT) or mutated (Mut) locus (Figure 5A, arrows).  
This insertion destabilizes the message or protein because supervillin is effectively absent from 
murine Svil -/- platelets (Figure 5C) and leukocytes (not shown).   
To assess the role of supervillin in platelet thrombus formation under shear stress, we 
analyzed wild-type and Svil-/- platelets in microfluidic flow chamber assays on immobilized 
collagen.21  No difference was observed under the “venous” flow rate of 400 sec-1 (Figure 6A-
6B), but Svil -/- platelets showed greater deposition (P<0.05) under arterial flow rates of 1200 
sec-1 (Figure 6C-E).  Both percent coverage of the collagen-coated area, indicating platelet 
adhesion to collagen, and sum intensity, indicating thrombus formation, were affected. 
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 Although there was no difference between wild-type and Svil-/- mice in platelet numbers, 
Svil-/- platelets appeared to be larger as measured by both forward scatter in flow cytometry 
and confocal microscopy (Table 3), consistent with the relationship in humans (Figure 4B).  
However, these larger platelets did not express correspondingly greater levels of major surface 
adhesion receptors, integrin IIb or glycoprotein Ib (Table 3).   
Supervillin directly binds F-actin, myosin II heavy chain, filamin, and many other 
cytoskeletal proteins.28-31  To better elucidate the cytoskeletal and structural differences between 
wild-type and Svil-/- platelets, we analyzed F-actin and myosin IIA organization using 
immunofluorescence confocal microscopy.  Although these platelet cytoskeletons are similar in 
appearance when statically adhered to glass (Figure 7A-B vs 7C-D), Svil-/- platelets are more 
highly spread after activation under high shear flow across collagen (Figure 7E-F vs 7G-H).  The 
intensity of F-actin staining increases after activation of both types of platelets, as expected 
given the associated polymerization of actin.32, 33 
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Discussion 
 
Inter-individual variation in platelet reactivity contributes to common arterial thrombotic 
disorders in humans, but there is only a limited understanding of the responsible molecular 
mechanisms.  We screened a cohort of healthy human subjects by genome-wide genotyping for 
associations with platelet function assessed under shear stress, and identified a candidate gene 
in AA that was validated using gene expression and platelet physiology approaches.  Our major 
findings were that 1) genetic variants in SVIL were associated with closure times in the PFA-
100ColA, 2) platelets contain supervillin and little or no archvillin or SmAV, and 3) low or absent 
platelet supervillin is associated with enhanced thrombus formation under high shear and 
increased platelet size in both humans and mice.   
Growing evidence supports a role for supervillin as a regulator of cytoskeletal-membrane 
interactions.  Among other functions, supervillin increases myosin II contractility, reduces 
integrin-mediated cell adhesion, and promotes rapid integrin recycling.34-36  Our data support an 
inhibitory role for supervillin in regulating the rapid activation and spreading of platelets during 
thrombus formation on collagen under shear stress, an important determinant of platelet 
responsiveness in arterial thrombosis.  These results are consistent with supervillin inhibition of 
spreading and integrin function in other cell types.44-45 
 Genome wide associations study.  The PFA-100® is dependent upon shear stress and 
is relatively “high-throughput.”  We appreciate that some12-15, but not all37, 38, clinical 
cardiovascular outcome studies have observed associations with PFA-100 results.  The lack of 
an association between PFA-100 results and clinical outcomes may be due to some non-
physiological conditions, such as anticoagulated blood or an absence of vessel wall.  It would be 
ideal to replicate our findings with other assays in humans, however neither light transmission 
aggregometry nor impedance aggregometry are performed under conditions considered to 
apply shear stress to platelets.  Our strategy was to use the GWAS as a screen for identifying 
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novel genes associated with shear-dependent platelet reactivity.  However, our study differs 
from prior platelet genomics studies in that our validation approach employed mRNA expression 
and physiology experiments.  Our statistical analysis was strengthened by the ability to adjust 
for confounders known to affect platelet adhesion (VWF activity) and aggregation (CD41 levels), 
which were also shown to be significant in the analysis.  Two SNPs in SVIL met the threshold 
for genome-wide significance in AA, and 3 additional SVIL SNPs associated with PFA-100ColA 
closure times with p values of 10-6. 
The reason for our inability to detect a similarly strong association in EA is unclear, but 
probably relates to limited power of a small sample size by typical GWAS standards and the fact 
that minor allele frequencies were ~20% lower in EAs.  Thus, much larger sample sizes might 
be necessary to detect an association in EAs.  Indeed, supplemental data in the genomic 
analysis by Johnson et al. show modest associations (~10-5) between SNPs in SVIL and in vitro 
platelet aggregation in both AAs and EAs 9. 
None of the 5 SVIL SNPs associated with PFA-100ColA closure times were predicted to 
affect the protein coding sequence, so we had no reason to suspect that any of these SNPs 
directly altered supervillin function.  This is not unusual since GWAS uses indirect association 
mapping with tagSNPs that are in LD with causal variants8.  However, despite a small sample 
size comprised of both EA and AA in our RNA expression study, eQTL analysis supported an 
association between these SNPs and SVIL mRNA levels (Figure 4C).  Thus, at least one 
genetic mechanism by which SVIL variants may regulate platelet reactivity is by altering SVIL 
expression, perhaps via effects on transcription or mRNA stability. 
 SVIL expression in platelets.  SVIL mRNA was detected in platelets using a 3’UTR probe 
that recognizes all SVIL transcripts and a 5’UTR probe specific for nonmuscle supervillin (Figure 
2).  Archvillin mRNAs were not detected in our microarray expression study, consistent with 
prior data indicating that archvillin and SmAV are mainly expressed in muscle 23.  In addition to 
the RNA data, immunoblotting with multiple antibodies demonstrated the presence of abundant 
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supervillin protein in platelets.  Using microarray analysis, Watkins et al. reported that SVIL 
mRNA is expressed in multiple hematopoietic cell types including CD4+ and CD8+ T-cells, 
CD14+ monocytes , CD19+ B-cells, CD56+ natural killer cells, and CD66b+ granulocytes 27.  We 
also observed SVIL mRNA in CD45+ cells (Figure 2C), found supervillin protein in murine 
thymocytes, splenocytes, macrophages, and neutrophils by immunoblotting (unpublished data), 
and recovered Coomassie blue-staining amounts of supervillin from bovine neutrophils 26.  
While high levels of proteases may have caused degradation in human leukocyte lysates 
(Figure 3), supervillin is clearly expressed at moderately high levels in platelets (Figures 2C and 
3, Suppl. Fig. 1).  And since PRP has some contamination with WBCs, our gene expression 
data suggest that SVIL mRNA is expressed at higher levels in platelets than WBCs (Fig. 2C).  
The basis for the reproducibly faster migration of platelet supervillin, as compared with HeLa 
and A549 cell supervillin (Figure 3), is unclear because the predicted mRNAs are identical.  A 
likely explanation is a cell type-specific difference in post-translational modifications. 
Supervillin and platelet size.  Supervillin expression levels are inversely correlated with 
platelet size in both humans and mice.  Although Svil-/- platelets are larger, they do not have 
greater surface expression of several critical adhesive glycoproteins (GPIb or integrin IIb), 
suggesting a possible membrane cytoskeletal defect, rather than premature release of larger 
platelets from megakaryocytes.  There are several possible mechanisms by which supervillin 
might regulate platelet size.  Filamin anchors the GPIb-IX-V complex to the platelet cytoskeleton 
and binds to supervillin 31, 39; an altered filamin-GPIb interaction could produce larger platelets, 
such as those characteristic of inherited mutations in the gene encoding GPIb 40, 41.  Other 
possible mechanisms include altered myosin II function similar to the MYH9-associated 
macrothrombocytopenias 42, or a simple disruption of the actin cytoskeleton that maintains 
normal platelet size, as in the Wiskott-Aldrich syndrome 43.  The increased platelet size may 
enhance thrombus formation since high platelet volumes have been associated with MI 16.  
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Supervillin and platelet function.  Supervillin effects on platelet function are most 
prominent under shear stress.  Healthy human subjects expressing higher levels of SVIL mRNA 
exhibit slower platelet thrombus formation in the PFA-100ColA.  Platelets in blood from 
supervillin-deficient mice form thrombi faster under high shear rates in flow chamber studies 
than is observed for platelets with wild-type Svil (Figure 6).  Although the effect of supervillin on 
platelet adhesion is not dramatic, it is difficult to demonstrate gain-of-function effects, and the 
increased adhesion observed in Svil null platelets is well in line with other mouse mutants of 
signaling molecules that limit platelet activation.44, 45  The mice used in these studies have Svil 
defects in all tissues, and we cannot exclude an indirect effect on platelets.  However, the SVIL 
association studies used here and by Johnson et al. 9 utilized an in vitro platelet assay 
consisting only of platelets and plasma (i.e., aggregometry).  Taken together, our results 
strongly suggest an inhibitory role for supervillin in platelet function.  .   
An inhibitory effect during spreading is consistent with the larger surface profiles 
observed for supervillin-deficient platelets on collagen after 2 min of flow under high shear 
(Figure 7).  The direction of this effect is consistent with a number of mechanisms.  First, the 
larger initial volumes of unactivated Svil-/- platelets (Table 3) may contribute to their larger 
surface areas after activation.  Second, the loss of supervillin could increase the rate of cell 
spreading by increasing integrin adhesion to the substrate, or by decreasing myosin II-mediated 
slowing of the cell spreading rate, as observed in other cell types 34, 35.  Finally, decreased 
integrity of the membrane-cytoskeleton connection could increase the apparent cross-sectional 
surface area if Svil-/- platelets are more sensitive to cortical disruption by high shear forces.  
Further studies are needed to determine which supervillin interactions regulate the early phases 
of platelet activation and adhesion under high-shear forces. 
There are potential clinical implications to our findings.  If confirmed in additional studies, 
these data suggest that SVIL variants may contribute to predisposition to cardiovascular 
disease in AA.  Targeting supervillin in a manner that would enhance its activity might have anti-
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thrombotic benefit for arterial vascular disease like MI and stroke, a benefit that may be more 
pronounced in African Americans.  Conversely, drugs that interrupt supervillin function in 
platelets could have untoward effects of promoting thrombosis.  Lastly, SNPs in strong LD with 
the causative SVIL variant may be useful as a biomarker for risk of thrombosis or hemorrhage. 
Summary.  Combined genome-wide technologies in a cohort with well-characterized 
platelet function have led to the identification of a novel protein in platelet biology.  We have 
identified a candidate gene meeting GWAS significance, and both human and mouse studies 
support an inhibitory effect of supervillin in platelet thrombus formation under shear stress.  
Although the causative variant in SVIL has not been identified, these data indicate that genetic 
variations in SVIL expression contribute to variations in human platelet reactivity and support a 
role for supervillin in arterial thrombosis.  Further analysis of SVIL variants may lead to a better 
understanding of the genetic basis for susceptibility to arterial thrombosis.  
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Figure Legends 
 
Figure 1 
GWAS with PFA-100ColA.  (A) Manhattan Plots for PFA-100ColA. The Manhattan plot is shown 
for all autosomes for European and African Americans.  The y-axis shows the –log10 of the p-
values for the chromosomes numbered on the x-axis.  For the African Americans the two most 
significant SNPs are rs7070678 and rs10826650 in SVIL; both meet genome-wide significance 
with p-values of 3.6x10-8 and 4.4x10-8, respectively.  None of the SNPs within SVIL meet 
genome-wide significance for European Americans.  (B)  SVIL region association plot on 
chromosome 10 for African Americans.  The most significant SNP rs7070678 is displayed, and 
the amount of linkage disequilibrium between this SNP and nearby SNPs is shown as a heat 
plot with SNPs in strongest LD with rs7070678 in darker colors.  The significance level is 
displayed on the y-axis as –log 10 of the p-values.  The rate of recombination within the region 
is shown as the light blue tracing.  The regions containing the SVIL and LYZL1 genes are 
indicated by green arrows. 
 
Figure 2 
SVIL genomic region and transcript expression.  (A) Exon structure of SVIL at 
Chr10:29,786,283-29,963,907 with exons of the two major transcripts (NM_003174, 
NM_021738) shown as lines and boxes.  The location of the 1st of the 5 SNPs (rs7070678) 
from Table 2 is shown by thin vertical arrows.  The locations of the microarray probes are 
indicated by the thick vertical arrows and ILMN ID numbers.  Horizontal arrows indicate the 
positions of the sense and antisense PCR primers.  (B) Ethidium-stained agarose gel showing 
RT-PCR products of leukocyte-depleted platelet (LDP) RNA and primers specific for ITGA2 
(CD41, integrin IIb) and SVIL.  Neg, no template control.  (C) Box plot showing the levels of 
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SVIL mRNA (ILMN_1671404) in LDP (n=29), PRP (n=11) and CD45+-leukocytes (WBC; n=5). 
Box represents interquartile range and whiskers represent 5% - 95% range.   
 
Figure 3 
Platelet supervillin expression.  (A) Immunoblot of PRP and, as a positive control, the A549 
human alveolar adenocarcinoma cell line.  Blots were probed with anti-supervillin (SVIL) and 
anti-CD41 (platelet integrin IIb) antisera and imaged on a LI-COR Odyssey. GAPDH, loading 
control.  (B) Supervillin protein schematic showing locations of the gelsolin/villin homology 
repeats, the binding sites for myosin II heavy chain (Myo II) and F-actin, and the epitopes for the 
4 antibodies used (H340, Ab50856, HPA02013 and S8695).  (C) Immunoblot probed with anti-
SVIL antibody S8695 and anti-CD45.  The erythroleukemia K562 and megakaryocytic Meg-01 
cell lines are included.  (D) Immunoblot with additional anti-SVIL antibodies.  (E) Immunoblot 
with H340 using lysates from mouse platelets and from A549 and HeLa adenocarcinoma cells, 
as controls. 
 
Figure 4 
Correlation of SVIL mRNA levels with human platelet function.  Natural log transformed SVIL 
mRNA levels (VSTs) from the gene expression profiling were correlated with (A) PFA-100ColA 
closure times, (B) mean platelet volume (MPV) and (C) SVIL expression levels based on 
rs7070678 genotype. 
 
Figure 5 
Disruption of the Svil gene and loss of Svil expression in platelets.  (A) Diagram of the wild-type 
(WT) and mutated (Mut) Svil loci (top 2 lines) with enlargements (bottom 2 lines) showing the 
insertion site (*) of the pGT0lxf vector sequence within the intron between coding exons 13 (E-
13) and 14 (E-14).  Also shown are the locations of PCR primer sets diagnostic for the wild-type 
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and mutant loci (arrows), the 0.8-kb probe used for Southern analyses, and the Bgl II sites 
(triangles) associated with endogenous genomic DNA and with the inserted -galactosidase-
neomycin (-gal/neo) coding sequence.  (B) PCR of genomic DNA from mouse tails using the 
primer sets shown in Panel A.  Primers specific for the insertion identify a ~2.5-kb product (Mut, 
top) while primers specific for the wild-type allele generate a 0.8-kb product (WT, below).  (C) 
Immunoblot of mouse platelets with anti-supervillin antibody (H340) and anti-tubulin as a loading 
control. 
 
Figure 6 
Enhanced adhesion and thrombus formation in platelets lacking supervillin.  Whole blood from 
wild type (WT, black line) or Svil-/- (SVIL, red line) mice was perfused over immobilized collagen 
at venous (400 s-1) or arterial (1200 s-1) shear conditions.  Platelets in whole blood were labeled 
with AlexaFluor488-labeled antibodies to platelet GPIX before perfusion.  (A, C) Surface area 
covered by platelets at indicated time points presented as % of coated collagen ± SEM.  (B, D) 
Sum fluorescence intensity ± SEM measured at the indicated time points.  Experiments shown 
in panels A-D were conducted on 4 different days for a total of 15 runs for each genotype.  (E) 
Representative images were taken at the designated times during perfusion at arterial (1200 s-1) 
shear rates.   Scale bars shown in 1-min images apply to all time points.  
 
Figure 7 
 
Immunofluorescence micrographs of (A, B, E, F) wild-type or (C, D, G, H) supervillin-deficient 
platelets fixed (A-D) statically onto glass or (E-H) after activation for 2 min on collagen under 
high-shear (1200 s-1) flow. F-actin (red) was visualized with AlexaFluor568-phalloidin; myosin 
IIA (green) was stained with antibody.  Bars, 2.5 µm, 0.5 µm, and 12.5 µm, as indicated. 
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Table 1. Demographics of subjects in this genetic study. 
 
Parameters African American European Americans 
No. of Subjects 116 125 
Females 69% 50% 
Mean Age (yrs) ± SD 35.0 ± 9.4 35.0 ± 11.1 
Mean BMI (kg/m2) ± SD 28.6 ± 5.3 25.5 ± 4.6 
Smokers 16.4% 32% 
Hypertension 8.6% 3.4% 
Hematocrit (%) ± SD 36.1 ± 5.0 37.4 ± 4.4 
Fibrinogen (mg/dL) ± SD 345 ± 99 300 ± 64 
VWF activity (%) ± SD 88 ± 38 79.7 ± 35 
PRP platelet count (per µL) ± SD 406,060 ± 93,350 430,550 ± 111,600 
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Table 2.  Most significant p-values detected in genotype data from African Americans 
SNP ID Chr:position Genes β Std 
Error 
MAF* Type P value 
rs7070678 10:29812602 SVIL 
-0.006807 0.001235 
.327 Exon 14 
synonymous 
3.581 x 10-8 
rs10826650 10:29814284 SVIL 
-0.006856 0.001253 
.340 Intron 13 4.426 x 10-8 
rs11858159 15:24824188 PWRN1 
0.005737 0.001169 
.366 Intron 7 9.1879 x 10-7 
rs3901472 15:24814582 PWRN1 
0.005773 0.001182 
.379 Intron 3 1.034 x 10-6 
rs7656730 4:40159617 N4BP2 
0.025637 0.005250 
.675 3’ UTR 1.044 x 10-6 
rs7910521 10:29803661 SVIL 
-0.006104 0.001279 
.326 Intron 16 1.830 x 10-6 
rs10826649 10:29792539 SVIL 
-0.006142 0.001301 
.297 Intron 17 2.382 x 10-6 
rs17783459 18:42329076 SETBP1 
0.032067 0.006898 
.042 Intron 3 3.343 x 10-6 
rs9890514 17:46738883 none 
0.012391 0.002675 
.196 - 3.604 x 10-6 
rs1507740 1:163075021 none 
0.013215 0.002885 
.157 - 4.640 x 10-6 
 
* Minor allele frequency 
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Table 3.  Platelet parameters in wild type and Svil -/- mice. 
Parameter wild type Svil -/- P value* 
Platelet number/L† 1,083,000 969,000 0.67 
Forward scatter‡ 19.4 23.2 <0.0001 
Surface area (µm2)§ 4.7 ± 0.1 (N=159) 5.3 ± 0.1 (N=241) 0.0045 
Integrin αIIb , MFI || fold change# 1.02 0.89 (n.s.) 
GPIbα, MFI || fold change# 1.30 0.40 (n.s.) 
 
* Calculated by Student’s T-Test 
† By Hemavet 850FS (Drew Scientific) 
‡ By FACScan (Becton Dickinson)  
§ Means ± s.e.m. by confocal microscopy of AlexaFluor568-phalloidin stained unactivated 
|| MFI, mean fluorescence intensity ratio of mutant/wild type platelets 
# Flow cytometric comparisons between mice are shown as fold-changes to normalize for day-
to-day variation in platelets, antibody fluorescence, binding, and acquisition. 
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